Laromestrocel
1 paper2 findings
- 1 lab
- Human trial1
Outcomes
2Soluble TIE2
downin humans1
1 study
Soluble TIE2
downin humans1
Laromestrocel decreases soluble TIE2 in humans.
“increasing doses of laromestrocel are associated with decreases in soluble (degraded) tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (TIE2)”
Human trial
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Cell stem cell25 Feb 2026
6-minute walk distance
upin humans1
1 study
6-minute walk distance
upin humans1
Laromestrocel increases 6-minute walk distance in humans (63.4 m (95% CI: 17.1-109.6 m; p = 0.0077)).
“Laromestrocel infusion results in clinically meaningful, dose- and time-dependent increases in the 6-min walk test (6MWT; primary endpoint) compared with placebo: 63.4 m (95% confidence interval [CI]: 17.1-109.6 m; p = 0.0077) at month 9”
Human trial9 months
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Cell stem cell25 Feb 2026
Development
- Companies
- LongeveronPhase 2hypoplastic left heart syndrome, aging frailty
Latest
1 in 12 monthsCell Stem Cell
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Randomised trial in 148 peopleInterventions